Department of Anesthesiology and Critical Care Medicine, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.
PLoS One. 2018 Apr 9;13(4):e0195576. doi: 10.1371/journal.pone.0195576. eCollection 2018.
Phenylephrine is an α1 adrenergic receptor agonist that causes pulmonary vasoconstriction, and so may effectively enhance hypoxic pulmonary vasoconstriction (HPV). However, there is little evidence that phenylephrine augments HPV in clinical situations. This study aimed to evaluate the clinical effects of phenylephrine infusion on oxygenation during one-lung ventilation (OLV) in patients undergoing thoracic surgery.
This was a prospective, randomized, double-blind, cross-over study. Included patients were those undergoing elective thoracic surgery in the lateral decubitus position with OLV. Patients were randomly allocated to two groups. The N-P group initially had OLV with normal saline infusion for 30 minutes; after a 10 minute interval, OLV was then maintained with phenylephrine infusion for 30 minutes. The P-N group had the drug-infusion in the reverse order. The primary outcome was arterial partial pressure of oxygen. Secondary outcomes were mean arterial pressure, heart rate, pulse pressure variation, perfusion index, and difference between bladder and skin temperature. Statistical analysis was performed using the student t-test, Fisher's exact test, and ANOVA for Cross-over design. P < 0.05 was considered statistically significant.
Twenty-nine patients were analyzed. Although phenylephrine infusion significantly increased mean arterial pressure (P < 0.001), arterial partial pressure of oxygen did not differ between the two timepoints (P = 0.19). There was no carryover effect in arterial partial pressure of oxygen (P = 0.14). Phenylephrine infusion significantly decreased heart rate (P = 0.02) and pulse pressure variation (P < 0.001).
Phenylephrine infusion did not improve oxygenation during OLV. The present results indicate that phenylephrine does not have clinically meaningful effects on HPV.
University Hospital Medical Information Network 000024317.
去氧肾上腺素是一种 α1 肾上腺素能受体激动剂,可导致肺血管收缩,因此可能有效增强低氧性肺血管收缩(HPV)。然而,在临床情况下,去氧肾上腺素增强 HPV 的证据很少。本研究旨在评估去氧肾上腺素输注对侧卧位行单肺通气(OLV)的胸外科患者氧合的临床影响。
这是一项前瞻性、随机、双盲、交叉研究。纳入的患者为在侧卧位行择期胸外科手术并接受 OLV 的患者。患者被随机分配到两组。N-P 组最初接受生理盐水输注 30 分钟的 OLV;10 分钟间隔后,用去氧肾上腺素输注维持 30 分钟的 OLV。P-N 组则以相反的顺序给予药物输注。主要结局为动脉血氧分压。次要结局为平均动脉压、心率、脉搏压变异、灌注指数和膀胱与皮肤温度差值。采用学生 t 检验、Fisher 确切检验和交叉设计的方差分析进行统计分析。P < 0.05 被认为具有统计学意义。
共分析了 29 例患者。尽管去氧肾上腺素输注显著增加平均动脉压(P < 0.001),但两个时间点的动脉血氧分压无差异(P = 0.19)。动脉血氧分压无交叉效应(P = 0.14)。去氧肾上腺素输注显著降低心率(P = 0.02)和脉搏压变异(P < 0.001)。
去氧肾上腺素输注并未改善 OLV 期间的氧合。本研究结果表明,去氧肾上腺素对 HPV 没有临床意义的影响。
大学医院医学信息网络 000024317。